Boss V, Wang X, Koppelman L F, Xu K, Murphy T J
Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Mol Pharmacol. 1998 Aug;54(2):264-72. doi: 10.1124/mol.54.2.264.
The nuclear factor of activated T cells (NFAT) mediates a cyclosporin A (CsA)- and FK506-suppressible transcriptional program in lymphocytes after antigen-stimulated phospholipase C activation. Nonlymphoid cells also express NFAT isoforms, raising the possibility that these isoforms can be regulated by other extracellular stimuli. This study sought to determine whether histamine can trigger NFAT-mediated transcription in human umbilical vein endothelial cells (HUVEC), using a retrovirus-based luciferase reporter driven by a well characterized, NFAT-specific enhancer. Luciferase levels are induced up to 60-fold over basal levels after costimulation of HUVEC with Ca2+-mobilizing drugs and a phorbol ester, a response that is 20-fold greater than that observed when HUVEC are stimulated with either drug alone. These synergistic responses are inhibited in cells treated with CsA. CsA and FK506 also inhibit the luciferase response to histamine, indicating that histamine can induce NFAT-mediated transcription in HUVEC. To identify candidate genes in HUVEC that might be regulated by NFAT, the expression of several chemokine mRNAs was measured after histamine treatment. Of the mRNAs tested, only those encoding monocyte chemotactic protein-1 (approximately 2-fold over basal) and interleukin-8 (approximately 6-fold over basal) are induced by histamine; both of these responses are suppressed by CsA and FK506. The H1 histamine receptor antagonist chlorpheniramine, but not the H2 receptor antagonist ranitidine, blocks the effects of histamine in this preparation. These data provide the first evidence for a physiological inducer of NFAT-mediated transcription in endothelial cells and support the hypothesis that NFAT participates in H1 histamine receptor-induced interleukin-8 gene expression.
活化T细胞核因子(NFAT)在抗原刺激磷脂酶C激活后介导淋巴细胞中受环孢菌素A(CsA)和FK506抑制的转录程序。非淋巴细胞也表达NFAT异构体,这增加了这些异构体可受其他细胞外刺激调节的可能性。本研究旨在确定组胺是否能在人脐静脉内皮细胞(HUVEC)中触发NFAT介导的转录,使用由特征明确的NFAT特异性增强子驱动的基于逆转录病毒的荧光素酶报告基因。在用钙动员药物和佛波酯共刺激HUVEC后,荧光素酶水平比基础水平诱导高达60倍,这一反应比单独用任何一种药物刺激HUVEC时观察到的反应大20倍。这些协同反应在用CsA处理的细胞中受到抑制。CsA和FK506也抑制荧光素酶对组胺的反应,表明组胺可在HUVEC中诱导NFAT介导的转录。为了鉴定HUVEC中可能受NFAT调节的候选基因,在组胺处理后测量了几种趋化因子mRNA的表达。在所测试的mRNA中,只有编码单核细胞趋化蛋白-1(比基础水平高约2倍)和白细胞介素-8(比基础水平高约6倍)的mRNA被组胺诱导;这两种反应均被CsA和FK506抑制。H1组胺受体拮抗剂氯苯那敏而非H2受体拮抗剂雷尼替丁可阻断组胺在此制剂中的作用。这些数据为内皮细胞中NFAT介导转录的生理诱导剂提供了首个证据,并支持NFAT参与H1组胺受体诱导的白细胞介素-8基因表达的假说。